Thrombotic thrombocytopenic purpura is a microvascular lesion with extensive formation of platelet thrombi within the microcirculation, the onset of which is most common in women aged 20-60 years. The clinical manifestations of the disease include microvascular hemolysis, depletion of platelets, neuropsychiatric symptoms, fever, renal damage, and involvement of vital organs such as the heart and lungs. The main treatment methods for thrombotic thrombocytopenic purpura are: 1, plasma replacement: the survival rate of patients with this disease can reach more than 85%, plasma replacement should be until the platelet count is normal and hemolytic symptoms disappear; 2, patients who are not qualified for plasma replacement can be plasma transfusion, but the efficacy is not as good as the former, but hereditary patients can be treated with plasma transfusion; 3, plasma replacement should be combined with the use of glycocorticoids until the disease is in remission; 3, plasma replacement should be used at the same time. Corticosteroids should be used in combination with plasma exchange until the disease is in remission; plasma exchange combined with rituximab can reduce relapse; 4. Because the disease is a platelet-consuming disease, platelet transfusion is contraindicated unless fatal bleeding or intracranial hemorrhage occurs. Since plasma exchange has been applied to the disease, the prognosis of the patients has been greatly improved. The disease has a tendency to recur, and the above treatment is still effective in patients with recurrence (please consult a specialist at a regular hospital for specific medication).